Medical devices

Dutch guidance on inducements by medical devices companies published

Iradj Nazaryar

On 31 August 2017, the Dutch Ministry of Health published Policy Rules providing guidance on the ban on inducements, which was introduced by the amendment of the Dutch Medical Devices Act of 17 May 2017.  The amendment establishes a prohibition on inducements, whether in cash or in kind, offered by medical device suppliers to professionals Read More

European and UK medical device industry bodies urge post-Brexit regulatory alignment

William Palmer

In a joint letter to the negotiators representing the UK and EU, medical device and in vitro diagnostic industry trade groups have urged both parties to ensure full regulatory implementation in their sector following “Brexit”, in March 2019.  The trade groups represented are MedTech Europe (MedTech), the Association of British Healthcare Industries (ABHI) and the Read More

UK position on Continuity in the Availability of Goods for the EU and the UK set out as Brexit negotiations continue

Erin Currie

A number of position papers have recently been published as negotiations continue on the UK’s withdrawal from the EU.  One such position paper from the UK is the Continuity in the availability of goods for the EU and the UK, published on 21 August 2017, which sets out proposals that will be applicable to the Read More

UK Life Sciences companies need full-cycle support to grow

Matthew Appleton

Now that the dust is settling after the publication of the UK’s “Life Sciences: industrial strategy”, it seems a good time to focus on one of the report’s key themes – growth. The report rightly notes that despite the UK having a strong track record in Life Sciences companies emerging, very few of those have Read More

EU sets out its position in Brexit negotiations on Intellectual Property Rights (including geographical indications)

Erin Currie

On 7 September 2017, the EU released a number of Brexit negotiation position papers, including one regarding Intellectual property rights which is of significant importance to the IP intensive Life Sciences industry.  The paper sets out the position of the EU27 on existing Intellectual Property (“IP”) rights and the exhaustion of those rights at the withdrawal date.  Read More